Fig. 10From: Preclinical evaluation of the theranostic potential of 89Zr/177Lu-labeled anti-TROP-2 antibody in triple-negative breast cancer modelTumor size and body weight monitoring of RIT studies. A The strongest anti-tumor efficacy was observed in the high-dose group, followed by the low-dose group. B The body weight of each group showed a downward trendBack to article page